Nanexa AB - Asset Resilience Ratio
Nanexa AB (NANEXA) has an Asset Resilience Ratio of 40.01% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Nanexa AB's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Nanexa AB's Asset Resilience Ratio has changed over time. See net asset quality index of Nanexa AB to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Nanexa AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Nanexa AB worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr66.69 Million | 40.01% |
| Total Liquid Assets | Skr66.69 Million | 40.01% |
Asset Resilience Insights
- Very High Liquidity: Nanexa AB maintains exceptional liquid asset reserves at 40.01% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nanexa AB Industry Peers by Asset Resilience Ratio
Compare Nanexa AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Nanexa AB (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Nanexa AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.35% | Skr36.40 Million ≈ $3.92 Million |
Skr138.14 Million ≈ $14.87 Million |
-11.46pp |
| 2023-12-31 | 37.81% | Skr50.00 Million ≈ $5.38 Million |
Skr132.26 Million ≈ $14.23 Million |
+37.81pp |
| 2022-12-31 | 0.00% | Skr-1.00K ≈ $-107.62 |
Skr170.19 Million ≈ $18.32 Million |
+0.02pp |
| 2021-12-31 | -0.02% | Skr-31.00K ≈ $-3.34K |
Skr165.00 Million ≈ $17.76 Million |
+0.17pp |
| 2020-12-31 | -0.19% | Skr-100.00K ≈ $-10.76K |
Skr53.69 Million ≈ $5.78 Million |
-- |
About Nanexa AB
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that ha… Read more